155 related articles for article (PubMed ID: 33205163)
1. Codon Deoptimization of UL54 in meq-Deleted Marek's Disease Vaccine Candidate Eliminates Lymphoid Atrophy but Reduces Vaccinal Protection.
Conrad SJ; Hearn CJ; Silva RF; Dunn JR
Avian Dis; 2020 Sep; 64(3):243-246. PubMed ID: 33205163
[TBL] [Abstract][Full Text] [Related]
2. Addition of a UL5 helicase-primase subunit point mutation eliminates bursal-thymic atrophy of Marek's disease virus ∆Meq recombinant virus but reduces vaccinal protection.
Hildebrandt E; Dunn JR; Cheng HH
Avian Pathol; 2015; 44(4):254-8. PubMed ID: 25968878
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of Marek's disease virus by codon pair deoptimization of a core gene.
Conrad SJ; Silva RF; Hearn CJ; Climans M; Dunn JR
Virology; 2018 Mar; 516():219-226. PubMed ID: 29407380
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus.
Sun P; Cui N; Liu L; Su S; Cheng Z; Chen R; Li Y; Cui Z
Poult Sci; 2020 Apr; 99(4):1939-1945. PubMed ID: 32241474
[TBL] [Abstract][Full Text] [Related]
5. Properties of a meq-deleted rmd5 Marek's disease vaccine: protection against virulent MDV challenge and induction of lymphoid organ atrophy are simultaneously attenuated by serial passage in vitro.
Lee LF; Kreager K; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
Avian Dis; 2013 Jun; 57(2 Suppl):491-7. PubMed ID: 23901766
[TBL] [Abstract][Full Text] [Related]
6. Fully Attenuated
Sun A; Zhao X; Zhu X; Kong Z; Liao Y; Teng M; Yao Y; Luo J; Nair V; Zhuang G; Zhang G
Microbiol Spectr; 2022 Dec; 10(6):e0287122. PubMed ID: 36350141
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the Viral Thymidine Kinase in a Meq-Deleted Recombinant Marek's Disease Virus Reduces Lymphoid Atrophy but Is Less Protective.
Conrad SJ; Oluwayinka EB; Heidari M; Mays JK; Dunn JR
Microorganisms; 2021 Dec; 10(1):. PubMed ID: 35056456
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.
Lee LF; Kreager KS; Arango J; Paraguassu A; Beckman B; Zhang H; Fadly A; Lupiani B; Reddy SM
Vaccine; 2010 Feb; 28(5):1294-9. PubMed ID: 19941987
[TBL] [Abstract][Full Text] [Related]
9. Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.
Lee LF; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
Vaccine; 2012 Jul; 30(34):5151-8. PubMed ID: 22687760
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens.
Chang S; Ding Z; Dunn JR; Lee LF; Heidari M; Song J; Ernst CW; Zhang H
Avian Dis; 2011 Sep; 55(3):384-90. PubMed ID: 22017035
[TBL] [Abstract][Full Text] [Related]
11. Ability of MEQ-deleted MDV vaccine candidates to adversely affect lymphoid organs and chicken weight gain.
Dunn JR; Silva RF
Avian Dis; 2012 Sep; 56(3):494-500. PubMed ID: 23050465
[TBL] [Abstract][Full Text] [Related]
12. A Common Live-Attenuated Avian Herpesvirus Vaccine Expresses a Very Potent Oncogene.
Conradie AM; Bertzbach LD; Bhandari N; Parcells M; Kaufer BB
mSphere; 2019 Oct; 4(5):. PubMed ID: 31597721
[TBL] [Abstract][Full Text] [Related]
13. Lorf9 deletion significantly eliminated lymphoid organ atrophy induced by meq-deleted very virulent Marek's disease virus.
Sun A; Luo J; Wan B; Du Y; Wang X; Weng H; Cao X; Zhang T; Chai S; Zhao D; Xing G; Zhuang G; Zhang G
Vet Microbiol; 2019 Aug; 235():164-169. PubMed ID: 31282374
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of immunoprotection between vaccination with meq-deleted Marek's disease virus and vaccine strain CVI988/Rispens].
Duan L; Su S; Wang Y; Li S; Sun P; Chen W; Cui Z
Wei Sheng Wu Xue Bao; 2014 Nov; 54(11):1353-61. PubMed ID: 25752142
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Gallid herpesvirus 2 with interrupted meq genes confers safe and efficacious protection against virulent field strains.
Zhang Y; Liu C; Yan F; Liu A; Cheng Y; Li Z; Sun G; Lv H; Wang X
Vaccine; 2017 Aug; 35(36):4695-4701. PubMed ID: 28754487
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988.
Ajithdoss DK; Reddy SM; Suchodolski PF; Lee LF; Kung HJ; Lupiani B
Virus Res; 2009 Jun; 142(1-2):57-67. PubMed ID: 19189855
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV.
Lee LF; Lupiani B; Silva RF; Kung HJ; Reddy SM
Vaccine; 2008 Mar; 26(15):1887-92. PubMed ID: 18313812
[TBL] [Abstract][Full Text] [Related]
18. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
[TBL] [Abstract][Full Text] [Related]
19. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses.
Gimeno IM; Dunn JR; Cortes AL; El-Gohary Ael-G; Silva RF
Avian Dis; 2014 Jun; 58(2):232-43. PubMed ID: 25055627
[TBL] [Abstract][Full Text] [Related]
20. Viral kinetics, shedding profile, and transmission of serotype 1 Marek's disease vaccine Rispens/CVI988 in maternal antibody-free chickens.
Islam T; Renz KG; Walkden-Brown SW; Ralapanawe S
Avian Dis; 2013 Jun; 57(2 Suppl):454-63. PubMed ID: 23901761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
